Cargando…

Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study

BACKGROUND: One main challenge in Helicobacter pylori (H. pylori) eradication is its increasing antibiotic resistance. Additionally, resistance rates vary between geographic areas and periods. However, data are limited since susceptibility testing is not routinely performed. Thus, it is valuable to...

Descripción completa

Detalles Bibliográficos
Autores principales: Azrad, Maya, Vazana, Dafna, On, Avi, Paritski, Maya, Rohana, Hanan, Roshrosh, Halim, Agay‐Shay, Keren, Peretz, Avi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786357/
https://www.ncbi.nlm.nih.gov/pubmed/36110057
http://dx.doi.org/10.1111/hel.12932
_version_ 1784858273048952832
author Azrad, Maya
Vazana, Dafna
On, Avi
Paritski, Maya
Rohana, Hanan
Roshrosh, Halim
Agay‐Shay, Keren
Peretz, Avi
author_facet Azrad, Maya
Vazana, Dafna
On, Avi
Paritski, Maya
Rohana, Hanan
Roshrosh, Halim
Agay‐Shay, Keren
Peretz, Avi
author_sort Azrad, Maya
collection PubMed
description BACKGROUND: One main challenge in Helicobacter pylori (H. pylori) eradication is its increasing antibiotic resistance. Additionally, resistance rates vary between geographic areas and periods. However, data are limited since susceptibility testing is not routinely performed. Thus, it is valuable to gather data regarding H. pylori's resistance rates in Israel that would aid in better adjustment of treatment. MATERIALS AND METHODS: The study included 540 H. pylori isolates, recovered from gastric biopsy samples of patients who had undergone endoscopy, during 2015–2020, at the Padeh Poriya Medical Center. Antibiotic susceptibility testing to amoxicillin, clarithromycin, metronidazole, levofloxacin, rifampicin, and tetracycline was performed using the Etest technique. Data regarding participants' sex, age, and ethnic group were collected. For every antibiotic and for multi‐resistance, generalized linear models were used to estimate crude and adjusted estimated differences in mean MIC and odds ratios (ORs) for every year, compared with the reference year 2015. RESULTS: The highest resistance rates were for clarithromycin and metronidazole (46.3% and 16.3%, respectively). Patients above 18 had higher resistance rate to rifampicin and multi‐resistance (3.3% and 14.8%), compared with patients under 18 (0.5% and 8.4%, respectively). Resistance rates for levofloxacin, rifampicin, and multi‐resistance were significantly higher among Arab patients, compared with Jewish patients. During the 6‐year surveillance, a significant annual trend in MIC for metronidazole and in ORs for metronidazole, levofloxacin, and multi‐resistance were observed (after adjustment). During 2020 compared with 2015, significant increased ORs were observed for levofloxacin and metronidazole [5.72 (1.03–31.84); 4.28 (1.30–14.14), respectively]. CONCLUSIONS: In light of the remarkable changes in antibiotic resistance of H. pylori during the study's period and the increasing resistance rates to various antibiotics, it is very important to continuously monitor H. pylori antibiotic susceptibly. In order to increase eradication rates of this bacterium, therapy regimes must be based on an updated antibiotic resistance data.
format Online
Article
Text
id pubmed-9786357
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97863572022-12-27 Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study Azrad, Maya Vazana, Dafna On, Avi Paritski, Maya Rohana, Hanan Roshrosh, Halim Agay‐Shay, Keren Peretz, Avi Helicobacter Original Articles BACKGROUND: One main challenge in Helicobacter pylori (H. pylori) eradication is its increasing antibiotic resistance. Additionally, resistance rates vary between geographic areas and periods. However, data are limited since susceptibility testing is not routinely performed. Thus, it is valuable to gather data regarding H. pylori's resistance rates in Israel that would aid in better adjustment of treatment. MATERIALS AND METHODS: The study included 540 H. pylori isolates, recovered from gastric biopsy samples of patients who had undergone endoscopy, during 2015–2020, at the Padeh Poriya Medical Center. Antibiotic susceptibility testing to amoxicillin, clarithromycin, metronidazole, levofloxacin, rifampicin, and tetracycline was performed using the Etest technique. Data regarding participants' sex, age, and ethnic group were collected. For every antibiotic and for multi‐resistance, generalized linear models were used to estimate crude and adjusted estimated differences in mean MIC and odds ratios (ORs) for every year, compared with the reference year 2015. RESULTS: The highest resistance rates were for clarithromycin and metronidazole (46.3% and 16.3%, respectively). Patients above 18 had higher resistance rate to rifampicin and multi‐resistance (3.3% and 14.8%), compared with patients under 18 (0.5% and 8.4%, respectively). Resistance rates for levofloxacin, rifampicin, and multi‐resistance were significantly higher among Arab patients, compared with Jewish patients. During the 6‐year surveillance, a significant annual trend in MIC for metronidazole and in ORs for metronidazole, levofloxacin, and multi‐resistance were observed (after adjustment). During 2020 compared with 2015, significant increased ORs were observed for levofloxacin and metronidazole [5.72 (1.03–31.84); 4.28 (1.30–14.14), respectively]. CONCLUSIONS: In light of the remarkable changes in antibiotic resistance of H. pylori during the study's period and the increasing resistance rates to various antibiotics, it is very important to continuously monitor H. pylori antibiotic susceptibly. In order to increase eradication rates of this bacterium, therapy regimes must be based on an updated antibiotic resistance data. John Wiley and Sons Inc. 2022-09-15 2022-12 /pmc/articles/PMC9786357/ /pubmed/36110057 http://dx.doi.org/10.1111/hel.12932 Text en © 2022 The Authors. Helicobacter published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Azrad, Maya
Vazana, Dafna
On, Avi
Paritski, Maya
Rohana, Hanan
Roshrosh, Halim
Agay‐Shay, Keren
Peretz, Avi
Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study
title Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study
title_full Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study
title_fullStr Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study
title_full_unstemmed Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study
title_short Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study
title_sort antibiotic resistance patterns of helicobacter pylori in north israel – a six‐year study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786357/
https://www.ncbi.nlm.nih.gov/pubmed/36110057
http://dx.doi.org/10.1111/hel.12932
work_keys_str_mv AT azradmaya antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT vazanadafna antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT onavi antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT paritskimaya antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT rohanahanan antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT roshroshhalim antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT agayshaykeren antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy
AT peretzavi antibioticresistancepatternsofhelicobacterpyloriinnorthisraelasixyearstudy